Endocrine Testing Market - Latest Advancements & Market Outlook 2018 to 2026

The Global Endocrine Testing Market, by Test (Thyroid, Insulin, Follicle Stimulating Hormone, Luteinizing, Hormone, Estradiol, Testosterone, Progesterone, Human chorionic gonadotropin, Prolactin, Cortisol DHEA-S, and Others), by Diagnostic Technology (Immunoassay, Tandem Mass Spectroscopy, Monoclonal and Polyclonal Antibody, Sensor Technologies, Clinical Chemistry, and Others), by End User (Hospitals, Diagnostic Laboratories, and others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 2.95 billion in 2017 and is projected to exhibit a CAGR of 4.9% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Browse 45 Market Data Tables and 35 Figures spread through 200 Pages and in-depth TOC on "Endocrine Testing Market - by Test (Thyroid, Insulin, Follicle Stimulating Hormone, Luteinizing, Hormone, Estradiol, Testosterone, Progesterone, Human chorionic gonadotropin, Prolactin, Cortisol DHEA-S and Others), by Diagnostic Technology (Immunoassay, Tandem Mass Spectroscopy, Monoclonal and Polyclonal Antibody, Sensor Technologies, Clinical Chemistry, and Others), by End User (Hospitals, Diagnostic Laboratories and others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Global forecast to 2026"

To know the latest trends and insights prevalent in the endocrine testing market, click the link below: https://www.coherentmarketinsights.com/market-insight/endocrine-testing-market-1755

Endocrine testing allows profiling of blood concentration of the various endocrine hormone. Over secretion and under secretion of endocrinal hormones results in to development of endocrinal disease. Various endocrinal disease such as hypothyroidism, hyperthyroidism, infertility, polycystic ovarian syndrome, hypo/hyperadrenocorticism, hypogonadism, diabetes, Multiple endocrine neoplasia I and II, Cushing’s disease, Gigantism (acromegaly) and other growth hormone problem and precocious puberty( Early Puberty). Endocrine diseases are caused due to various reasons such as problem in endocrine feedback system, disease condition, and failure of stimulation of glands to release hormones, tumor of an endocrine gland, genetic disorders, infection and physical trauma to an endocrine gland. Increasing prevalence of these disease especially hypothyroidism, infertility, and diabetes are expected to drive growth of the global endocrinal testing market. According to study published by Centre for Disease Control and Prevention (CDC), in 2017, around 100 million (30.3 million diabetes and 84.1 million prediabetes) U.S. adults were suffering from diabetes or prediabetes condition. According to American Thyroid Association, 2017, around 12% of U.S. adults are estimated to develop thyroid disease in their lifetime. Postmenopausal osteoporosis caused due to reduced estrogen production after menopause leading to low bone mineral density and increased risk for fracture risks. It is estimated that osteoporosis affects around 10 million American adults annually, 34 million people are at high risk of it due to low bone mass, according to study published by BMC Endocrine Disorder in February 2018.

Key players are undergoing strategic mergers, acquisitions, and collaborations in order to maintain leading position in market and to tap the new market. In August 2017, North West London Pathology under National Health Service Trust and Abbott Laboratories signed contract worth US$ 252 million under which Abbott Laboratories will supply all analytical equipment and consumables, this contract would manage 26 million tests annually. In 2017, Abbott Laboratories received the U.S. Food and Drug Administration (FDA) 510(k) clearance for its Alinity ci-series instruments for clinical chemistry and immunoassay diagnostics. In April 2018, Beckman Coulter launched its Access Sensitive Estradiol assay in the U.S. market, also made available its assay in the most of global markets. This test accurately detects estradiol levels in women, children, and men using low sample. Company also launched Anti-Müllerian Hormone (AMH) assay in 2017, which helps in clinical management of women suffering from infertility. In 2016, company received FDA clearance and commercially launched new Access TSH (3rd IS) assay.

To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/insight/request-sample/1755

Key Takeaways of the Endocrine Testing Market:

• The global endocrine testing market is expected to exhibit a CAGR of 4.9% over the forecast period, owing to increasing prevalence of endocrine disease and need for their early diagnosis.
• Among test type, thyroid test segment is expected to hold a dominant position in market during the forecast period due to increasing number of thyroid disorders and its high prevalence. Thyroid test would be followed by fertility related hormone testing (FSH, Progesterone etc.) due to high incidence if infertility throughout globe. Amongst diagnostic technology segment, tandem mass spectroscopy would gain maximum share due to high accuracy and short time to detect the analyte in sample, amongst end user hospitals would prevail over other end user.
• North America region is expected to hold dominant position in the global endocrine testing market, followed by Europe and Asia Pacific. The U.S. has high prevalence of endocrine disease such as hypo/hyperthyroidism. For instance, According to American Thyroid Association, in 2017, around 60% of people suffering from thyroid disease are unaware of their disease. Europe region is expected to witness growth in endocrine testing market, owing to increasing number of population age 65 and above. According to European statistics 2017, around 19% of European population was 65 and above in 2016. Emerging economies from Asia Pacific region are expected to present potential opportunity as this region is facing increasing number in endocrine disorder.
• Key players operating in the endocrine testing market include Abbott Laboratories, Thermo Fisher Scientific, Beckman Coulter, Inc., Siemens Healthineers, bioMérieux SA, Agilent Technologies, Bi-Rad Laboratories, AB Sciex, F-Hoffmann La Roche AG, Quest Diagnostics, and others

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services